Barth syndrome is a rare, X-linked genetic disorder caused by mutations in the TAZ gene, which provides instructions for an enzyme called tafazzin. Because the gene sits on the X chromosome, the condition overwhelmingly affects boys and men, though female carriers can pass it on. The hallmark features include heart muscle disease, low white blood cell counts, skeletal muscle weakness, and growth delay, but the severity and combination of symptoms vary widely from person to person. A large database maintained by the Barth Syndrome Foundation has tracked over 500 affected individuals, offering the clearest picture yet of how the disease unfolds across a lifetime.
What Causes Barth Syndrome at the Cellular Level
The root problem is a faulty version of the enzyme tafazzin. In healthy cells, tafazzin sits inside mitochondria and reshapes a specialized fat molecule called cardiolipin by swapping fatty acid chains between phospholipids.1PubMed Central. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase Cardiolipin is found almost exclusively in the inner mitochondrial membrane, where it helps organize the protein complexes that produce cellular energy. Tafazzin converts an immature form of cardiolipin into a mature, functional version by preferentially transferring a specific fatty acid from another phospholipid.2PubMed Central. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome – Section: Abstract
When tafazzin is absent or defective, mature cardiolipin levels drop and a precursor molecule called monolysocardiolipin (MLCL) accumulates.3PubMed Central. An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin/cardiolipin ratio The ratio of MLCL to cardiolipin rises dramatically in affected individuals and serves as a key biochemical marker for diagnosis.4PubMed Central. Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype The downstream effects cascade through the mitochondria: the large protein supercomplexes that form the respiratory chain become destabilized, and the internal folds of the mitochondrial membrane (called cristae) lose their normal architecture.5Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution In practical terms, the cell’s power plants are structurally compromised, and the tissues that need the most energy, particularly heart muscle and skeletal muscle, suffer the most.
How It Is Inherited
Barth syndrome follows an X-linked recessive pattern. Males have one X chromosome, so a single mutated copy of the TAZ gene is enough to cause the disease. Females carry two X chromosomes, meaning a mutation on one copy is typically compensated by the healthy copy on the other. This is why clinical disease is seen almost exclusively in boys and men. A mother who carries one mutated TAZ copy has a 50 percent chance of passing it to each son, who would then be affected.
Interestingly, research into why female carriers remain healthy has revealed a biological safety mechanism. A study of 16 obligate carriers from six families found that most showed significantly skewed X-chromosome inactivation, meaning their cells preferentially silenced the X chromosome carrying the mutation and kept the healthy copy active. Eleven of the 16 carriers had a skewed inactivation pattern, and in seven carriers where parental origin could be determined, the inactivated X was always the one inherited from the mother carrying the mutation.6PubMed Central. X chromosome inactivation in carriers of Barth syndrome This selective silencing appears to be the result of cells with the active mutant gene being at a survival disadvantage and gradually being outcompeted during development.
The Cardiac Features
Heart disease is the most clinically significant and often the earliest feature. The forms of cardiomyopathy seen in Barth syndrome are diverse: dilated cardiomyopathy, hypertrophic cardiomyopathy, endocardial fibroelastosis, and left ventricular noncompaction have all been reported.7PubMed Central. Barth syndrome Left ventricular noncompaction and dilated cardiomyopathy are the most common cardiac presentations and can produce symptoms of heart failure as well as dangerous rhythm disturbances.8PubMed Central. Barth syndrome Some patients experience an undulating cardiac phenotype, where heart function waxes and wanes over time, sometimes deteriorating enough to require mechanical circulatory support or transplantation.9PubMed. Left ventricular noncompaction cardiomyopathy in Barth syndrome: an example of an undulating cardiac phenotype necessitating mechanical circulatory support as a bridge to transplantation
Ventricular arrhythmias are a particular concern. Case reports have documented cardiac arrest and the need for implantable defibrillators, and researchers have argued that these arrhythmias are part of the primary disease phenotype rather than a secondary complication.10PubMed. Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome Patients remain at risk for malignant arrhythmias and cardiac death throughout life, making ongoing cardiac monitoring essential.11Progress in Pediatric Cardiology. ECG findings are poor predictors for adverse events and cardiac death in Barth syndrome – Section: Abstract One frustrating clinical reality is that standard ECG findings have proven to be poor predictors of which patients will go on to have adverse cardiac events, which complicates risk stratification.
Neutropenia and Infection Risk
Low neutrophil counts are the second defining feature. In a study of 88 patients, roughly 84 percent had at least one neutrophil count below the normal threshold, and about 44 percent had severe chronic neutropenia with multiple counts dropping very low.12PubMed Central. Neutropenia in Barth syndrome: characteristics, risks, and management – Section: Abstract The pattern varies considerably: some individuals have intermittent and unpredictable dips, others have persistently low counts, and a subset show mathematically regular cyclical oscillations. This unpredictability makes clinical management tricky, because a patient whose blood count looks fine on Monday may be dangerously neutropenic on Thursday.
In a French national cohort of 22 patients, severe neutropenia at the time of diagnosis was identified as one of two prognostic factors correlated with survival, the other being year of birth (reflecting improvements in care over time).13PubMed Central. Natural history of Barth syndrome: a national cohort study of 22 patients – Section: RESULTS Recurrent bacterial infections are a predictable consequence of chronically low neutrophil counts and remain a significant source of illness and hospitalization, particularly in early childhood. Granulocyte colony-stimulating factor (G-CSF) is sometimes used to boost neutrophil production, though clinical approaches vary by center.
Skeletal Muscle Weakness and Exercise Intolerance
Beyond the heart, mitochondrial dysfunction takes a heavy toll on skeletal muscle. Boys and men with Barth syndrome typically experience reduced muscle strength, delayed motor milestones in early childhood, and pronounced exercise intolerance that persists into adulthood.14PubMed Central. Barth syndrome: mechanisms and management Research into the exercise physiology of affected individuals has shown that the problem is twofold: cardiac output is impaired, and skeletal muscles themselves are unable to extract and use oxygen normally. In one study, muscle tissue oxygen measurements during exercise moved in the opposite direction from what is expected, indicating that the skeletal muscle mitochondrial defect is independent of the heart problem.15PubMed. Impaired cardiac reserve and severely diminished skeletal muscle Oâ‚‚ utilization mediate exercise intolerance in Barth syndrome
This distinction matters because it has practical implications for treatment expectations. A pilot study suggested that supervised resistance exercise training could improve muscle strength in Barth syndrome, hinting that some of the weakness is treatable even if the underlying mitochondrial defect remains.16PubMed Central. Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study But exercise programs have to be carefully tailored, given the cardiac risks involved.
Growth, Feeding, and Other Features
Growth delay is common in young children with Barth syndrome, though the ratio of height to weight is often preserved, meaning boys tend to be smaller overall rather than disproportionately thin or short. Feeding difficulties in infancy and early childhood frequently contribute to failure to thrive and may require nutritional support. Other reported features include characteristic facial appearance, cognitive differences, low blood sugar episodes, elevated lactic acid, and pubertal delay.17PubMed Central. Barth syndrome The phenotype is highly variable: some patients present in infancy with life-threatening heart failure, while others are not diagnosed until later childhood or even adulthood, particularly if their cardiac symptoms are mild.
The urinary excretion of a compound called 3-methylglutaconic acid is often elevated in Barth syndrome and historically served as an early diagnostic clue. However, this finding is inconsistent. Some patients show only modest or intermittent elevations, and the same marker appears in several other mitochondrial disorders. The MLCL-to-cardiolipin ratio in blood spots has emerged as a more reliable biochemical test.18PubMed Central. An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin/cardiolipin ratio Genetic sequencing of the TAZ gene provides definitive confirmation.
Survival and the Changing Prognosis
Early childhood is the highest-risk period. Data from the Barth Syndrome Foundation’s database of 502 affected individuals found a 59 percent transplant-free survival rate for children under age five. Between ages 5 and 25, the risk of death plateaus considerably before rising again later in life.19PubMed Central. Survival and Clinical Progression in Barth Syndrome: Insights From the Barth Syndrome Foundation’s Database of 502 Affected Individuals The implication is that boys who survive early childhood enter a relatively stable period, though the clinical burden of the disease continues to accumulate.
Adults with Barth syndrome report that tiredness, muscle weakness, and fast or irregular heartbeat are the most consistently troublesome symptoms, and that these generally worsen over time. The impact extends beyond physical health: affected individuals describe increasing interference with work, family activities, and leisure as they age.20PubMed Central. Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study Quality-of-life assessments confirm that physical and school functioning are the most impaired domains, based on both self-reports and parent reports.21PubMed Central. Quality of life in Barth syndrome
Heart Transplantation and Its Limits
When heart failure becomes unmanageable with medications, cardiac transplantation is sometimes the only option. Outcomes appear reassuring: in a study of 43 heart transplants in Barth syndrome patients, survival was no different from non-Barth transplant recipients, and freedom from acute rejection was actually greater in the Barth group. The median age at transplant was about 1.7 years, reflecting how early cardiac disease can become life-threatening. Mechanical support devices were used as a bridge to transplant in roughly a third of cases.22PubMed. Favorable outcomes after heart transplantation in Barth syndrome – Section: RESULTS
However, transplantation fixes only part of the problem. Research comparing transplanted and non-transplanted individuals with Barth syndrome found that exercise tolerance, muscle mass, and skeletal muscle energy metabolism did not improve after heart transplant.23JIMD Reports. Cardiac Transplantation Does Not Improve Exercise Tolerance, Muscle Mass, or Substrate Metabolism in Barth Syndrome This makes sense given what we know about the skeletal muscle oxygen-extraction defect described earlier: the mitochondrial dysfunction in skeletal muscle is intrinsic and does not go away when the heart is replaced. A new heart can be life-saving, but families should understand that the muscle weakness and fatigue will persist.
Supportive Care and Nutrition
Day-to-day management of Barth syndrome requires a multidisciplinary team, typically including cardiologists, hematologists, metabolic specialists, physical therapists, and dietitians. A systematic review of management strategies emphasized the importance of a flexible, individualized approach.24PubMed Central. Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach – Section: Interventions Nutritional interventions commonly used in the Barth population include cornstarch given before bedtime to help prevent overnight low blood sugar, supplemental amino acids to support muscle maintenance, and magnesium, potassium, and multivitamin supplementation.
Cardiac medications such as ACE inhibitors, beta-blockers, and diuretics are used to manage heart failure symptoms, following the same general principles used in other forms of pediatric cardiomyopathy. Antibiotic prophylaxis or G-CSF may be used during periods of severe neutropenia or ahead of procedures that carry infection risk. Monitoring frequency tends to be high, with regular echocardiograms, blood counts, and metabolic panels. Because the cardiac phenotype can fluctuate unpredictably, clinicians often err on the side of closer surveillance than might seem warranted by a patient’s current status.
Elamipretide and Other Emerging Therapies
The most advanced experimental therapy for Barth syndrome is elamipretide, a small peptide that targets the inner mitochondrial membrane and is thought to stabilize cardiolipin-containing structures. A phase 2/3 clinical trial (called TAZPOWER) initially failed to meet its primary endpoints during the randomized, controlled portion of the study. But during the subsequent open-label extension phase, when all participants received the drug, significant improvements emerged: walking distance on a six-minute walk test increased by about 96 meters, and self-reported fatigue scores improved. Cardiac measurements also trended in a positive direction over 168 weeks of treatment.25PubMed. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER At 36 weeks in the open-label phase, walking distance had improved by about 96 meters and knee extensor strength also increased significantly.26PubMed Central. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome – Section: RESULTS
The fact that the randomized phase did not reach significance while the open-label extension did is worth flagging. Open-label results, where patients know they are receiving the drug, are inherently less rigorous because placebo effects and expectation bias can influence both patient-reported outcomes and effort on physical tests. The improvements are encouraging and the long-term tolerability data are reassuring, but the evidence remains a step below what a clean positive randomized trial would provide. Regulatory decisions on elamipretide for Barth syndrome are still evolving.
Gene Therapy Research
Because Barth syndrome is caused by loss of function of a single gene, it is a natural candidate for gene replacement therapy. Preclinical work in mouse models has been promising. In one set of experiments, mice engineered to lack the TAZ gene developed severe dilated cardiomyopathy and skeletal muscle disease that closely mirrored the human condition. Treatment with an adeno-associated virus (AAV) vector carrying a working human TAZ gene not only prevented heart dysfunction when given to newborn mice but also reversed established cardiac disease and fibrosis in older mice.27PubMed Central. AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome
A separate study compared different AAV vectors and found that a version using a desmin promoter, which drives gene expression primarily in muscle tissue, provided the most broadly effective results across multiple assessments in both neonatal and adult mice.28PubMed Central. AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome The appeal of gene therapy for Barth syndrome is that it could, in theory, address both the cardiac and skeletal muscle components of the disease simultaneously, something that heart transplantation alone cannot do. Translation to human trials is the next hurdle, and the usual caveats about moving from mice to people apply: dosing, immune responses to the viral vector, and long-term durability of gene expression all need to be worked out.
Why Barth Syndrome Is Underdiagnosed
Despite being first described in the 1980s, Barth syndrome remains significantly underdiagnosed. The variable presentation is a major reason. A boy who presents with isolated cardiomyopathy may never have his neutrophil counts scrutinized. A boy with unexplained neutropenia may not receive an echocardiogram. The features that together form a recognizable pattern are, individually, common enough that each one can easily be attributed to something else. Dilated cardiomyopathy in an infant triggers a workup for viral myocarditis or idiopathic causes. Neutropenia triggers a hematology referral. Muscle weakness triggers a neurology evaluation. Without someone stepping back to connect the dots, the underlying syndrome goes unrecognized.
The availability of genetic testing and the MLCL-to-cardiolipin blood spot assay have made diagnosis more accessible, but clinicians first have to think of Barth syndrome to order those tests. Awareness campaigns by the Barth Syndrome Foundation and inclusion of TAZ on expanded genetic panels for cardiomyopathy have helped, but the condition still has an outsized gap between estimated genetic prevalence and confirmed diagnoses. Any boy with unexplained cardiomyopathy, particularly left ventricular noncompaction or dilated cardiomyopathy presenting in infancy, warrants consideration of Barth syndrome, especially if neutropenia, muscle weakness, or growth delay is also present.
Living With the Condition as an Adult
Adults with Barth syndrome navigate a daily reality shaped by persistent fatigue and physical limitations. In qualitative interviews, individuals described a progressive narrowing of what they could comfortably do: activities they managed as teenagers became more difficult in their twenties and thirties. Paid employment, household tasks, and social participation all suffered as tiredness and weakness accumulated over the years.29PubMed Central. Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study Short stature in youth was another commonly reported experience, though adult heights varied. The emotional toll is real and underappreciated: growing up with visible physical limitations and chronic fatigue in a society built around able-bodied norms creates challenges that purely medical management does not address.
The data from 502 individuals tracked by the Barth Syndrome Foundation reinforce this picture, showing that while the risk of death and hospitalization plateaus during the school-age and young-adult years, the overall clinical burden of the disease continues to increase throughout life.30PubMed Central. Survival and Clinical Progression in Barth Syndrome: Insights From the Barth Syndrome Foundation’s Database of 502 Affected Individuals Psychosocial support, vocational counseling, and adaptive strategies for managing energy are as important as the echocardiograms and blood draws, even if they receive far less clinical attention.